Menu
Search
|

Menu

Close
X

Onconova Therapeutics Inc ONTX.OQ (NASDAQ Stock Exchange Capital Market)

5.95 USD
+0.09 (+1.54%)
As of Oct 19
chart
Previous Close 5.86
Open 5.91
Volume 25,476
3m Avg Volume 21,237
Today’s High 5.99
Today’s Low 5.75
52 Week High 39.00
52 Week Low 4.99
Shares Outstanding (mil) 9.85
Market Capitalization (mil) 17.24
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY18
1
FY17
1
FY16
6
FY15
11
EPS (USD)
FY18
-0.410
FY17
-2.837
FY16
-5.712
FY15
-11.134
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.65
Price to Sales (TTM)
vs sector
7.31
5.82
Price to Book (MRQ)
vs sector
--
4.89
Price to Cash Flow (TTM)
vs sector
--
22.93
Total Debt to Equity (MRQ)
vs sector
--
17.17
LT Debt to Equity (MRQ)
vs sector
--
12.75
Return on Investment (TTM)
vs sector
-307.64
14.28
Return on Equity (TTM)
vs sector
-4,335.58
16.00

EXECUTIVE LEADERSHIP

Michael Hoffman
Chairman of the Board, Since 2006
Salary: --
Bonus: --
Steven Fruchtman
President, Since 2018
Salary: --
Bonus: --
Ramesh Kumar
Chief Executive Officer, Director, Since 2018
Salary: $525,000.00
Bonus: $188,409.00
Mark Guerin
Chief Financial Officer, Since 2016
Salary: --
Bonus: --
Manoj Maniar
Senior Vice President - Product Development, Since 2005
Salary: $356,860.00
Bonus: $108,664.00

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

375 Pheasant Run
NEWTOWN   PA   18940

Phone: +1267.7593681

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company's lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib.

SPONSORED STORIES